{"id":190786,"date":"2026-08-07T13:08:24","date_gmt":"2026-08-07T07:38:24","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=190786"},"modified":"2026-08-07T13:08:25","modified_gmt":"2026-08-07T07:38:25","slug":"pros-cons-investing-syngene-share","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/pros-cons-investing-syngene-share\/","title":{"rendered":"Syngene International Share: Pros and Cons Every Investor Must Know in 2026"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p style=\"border-left: 4px solid #1F4E79; background: #EBF3FB; padding: 10px 16px; font-style: italic;\"><em>Syngene International share CMP approx Rs 400. 52W High Rs 520. Market Cap approx Rs 16,413 Cr. PE 74.33x. Biocon-promoted integrated CDMO (contract research and manufacturing organisation) with global pharma clients.<\/em><\/p>\n<p>Syngene International is India&#8217;s most respected integrated CDMO (Contract Research, Development, and Manufacturing Organisation), providing drug discovery research, clinical development, and commercial manufacturing services to global pharmaceutical and biotech companies. The Syngene share at approximately 74x PE reflects global CDMO demand but is expensive relative to current ROE of 7.76 percent during a capital investment phase that is temporarily suppressing returns.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&amp;utm_medium=syngene-pros-cons\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/pros-cons-investing-syngene-share\/#About_Syngene_International\" title=\"About Syngene International\">About Syngene International<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/pros-cons-investing-syngene-share\/#Key_Financial_Snapshot_Syngene_International_Share\" title=\"Key Financial Snapshot: Syngene International Share\">Key Financial Snapshot: Syngene International Share<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/pros-cons-investing-syngene-share\/#Pros_of_Investing_in_Syngene_International_Share\" title=\"Pros of Investing in Syngene International Share\">Pros of Investing in Syngene International Share<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/pros-cons-investing-syngene-share\/#1_Integrated_CDMO_Covering_Drug_Discovery_to_Commercial_Manufacturing_%E2%80%94_Rare_Capability\" title=\"1. Integrated CDMO Covering Drug Discovery to Commercial Manufacturing \u2014 Rare Capability\">1. Integrated CDMO Covering Drug Discovery to Commercial Manufacturing \u2014 Rare Capability<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/pros-cons-investing-syngene-share\/#2_Global_Pharma_Client_Base_%E2%80%94_Bristol-Myers_Squibb_Abbott_Amgen_%E2%80%94_Validating_Quality\" title=\"2. Global Pharma Client Base \u2014 Bristol-Myers Squibb, Abbott, Amgen \u2014 Validating Quality\">2. Global Pharma Client Base \u2014 Bristol-Myers Squibb, Abbott, Amgen \u2014 Validating Quality<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/pros-cons-investing-syngene-share\/#3_Biocon_Group_Promoter_Providing_Pharmaceutical_Industry_Knowledge_and_Client_Relationships\" title=\"3. Biocon Group Promoter Providing Pharmaceutical Industry Knowledge and Client Relationships\">3. Biocon Group Promoter Providing Pharmaceutical Industry Knowledge and Client Relationships<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/pros-cons-investing-syngene-share\/#4_Global_CDMO_Industry_Tailwind_%E2%80%94_Drug_Discovery_Outsourcing_Growing_12_to_15_Percent\" title=\"4. Global CDMO Industry Tailwind \u2014 Drug Discovery Outsourcing Growing 12 to 15 Percent\">4. Global CDMO Industry Tailwind \u2014 Drug Discovery Outsourcing Growing 12 to 15 Percent<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/pros-cons-investing-syngene-share\/#5_Dedicated_Research_Facility_Infrastructure_on_Mangalore_Campus_Attracting_Long-Term_Partners\" title=\"5. Dedicated Research Facility Infrastructure on Mangalore Campus Attracting Long-Term Partners\">5. Dedicated Research Facility Infrastructure on Mangalore Campus Attracting Long-Term Partners<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/pros-cons-investing-syngene-share\/#Cons_of_Investing_in_Syngene_International_Share\" title=\"Cons of Investing in Syngene International Share\">Cons of Investing in Syngene International Share<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/pros-cons-investing-syngene-share\/#1_PE_of_74x_Is_Expensive_for_CDMO_in_Investment_Phase_With_Low_ROE_of_78_Percent\" title=\"1. PE of 74x Is Expensive for CDMO in Investment Phase With Low ROE of 7.8 Percent\">1. PE of 74x Is Expensive for CDMO in Investment Phase With Low ROE of 7.8 Percent<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/pros-cons-investing-syngene-share\/#2_ROE_of_776_Percent_Is_Well_Below_Quality_Threshold_%E2%80%94_Investment_Cycle_Impact\" title=\"2. ROE of 7.76 Percent Is Well Below Quality Threshold \u2014 Investment Cycle Impact\">2. ROE of 7.76 Percent Is Well Below Quality Threshold \u2014 Investment Cycle Impact<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/pros-cons-investing-syngene-share\/#3_Global_Pharma_CDMO_Competition_From_WuXi_AppTec_and_Samsung_Biologics\" title=\"3. Global Pharma CDMO Competition From WuXi AppTec and Samsung Biologics\">3. Global Pharma CDMO Competition From WuXi AppTec and Samsung Biologics<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/pros-cons-investing-syngene-share\/#4_Client_Programme_Cancellation_Risk_%E2%80%94_Early-Stage_Drug_Failures_Reduce_Research_Revenue\" title=\"4. Client Programme Cancellation Risk \u2014 Early-Stage Drug Failures Reduce Research Revenue\">4. Client Programme Cancellation Risk \u2014 Early-Stage Drug Failures Reduce Research Revenue<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/pros-cons-investing-syngene-share\/#Is_Syngene_International_Share_a_Good_Investment_in_2026\" title=\"Is Syngene International Share a Good Investment in 2026?\">Is Syngene International Share a Good Investment in 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/pros-cons-investing-syngene-share\/#Key_Risks_of_Syngene_International_Share\" title=\"Key Risks of Syngene International Share\">Key Risks of Syngene International Share<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/pros-cons-investing-syngene-share\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/pros-cons-investing-syngene-share\/#Frequently_Asked_Questions_on_Syngene_International_Share\" title=\"Frequently Asked Questions on Syngene International Share\">Frequently Asked Questions on Syngene International Share<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/pros-cons-investing-syngene-share\/#What_are_the_main_pros_of_Syngene_International_share\" title=\"What are the main pros of Syngene International share?\">What are the main pros of Syngene International share?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/pros-cons-investing-syngene-share\/#What_are_the_key_risks_of_Syngene_International_share\" title=\"What are the key risks of Syngene International share?\">What are the key risks of Syngene International share?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/pros-cons-investing-syngene-share\/#Is_Syngene_International_share_a_good_investment_in_2026\" title=\"Is Syngene International share a good investment in 2026?\">Is Syngene International share a good investment in 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/pros-cons-investing-syngene-share\/#What_is_the_52-week_range_of_Syngene_International_share\" title=\"What is the 52-week range of Syngene International share?\">What is the 52-week range of Syngene International share?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/pros-cons-investing-syngene-share\/#What_is_a_CDMO_and_how_does_Syngene_provide_this_service\" title=\"What is a CDMO and how does Syngene provide this service?\">What is a CDMO and how does Syngene provide this service?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/univest.in\/blogs-2\/pros-cons-investing-syngene-share\/#What_is_the_BMS_dedicated_research_facility_at_Syngene\" title=\"What is the BMS dedicated research facility at Syngene?\">What is the BMS dedicated research facility at Syngene?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"About_Syngene_International\"><\/span><strong>About Syngene International<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Syngene International Limited (NSE: SYNGENE) is a Bengaluru-based CDMO, majority owned by Biocon Group. Founded in 1993, it provides integrated drug discovery chemistry, biology, toxicology, clinical development manufacturing, and commercial API manufacturing to over 400 global pharmaceutical clients including Bristol-Myers Squibb, Abbott, and Amgen. The Syngene share is India&#8217;s premier listed CDMO investment.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Financial_Snapshot_Syngene_International_Share\"><\/span><strong>Key Financial Snapshot: Syngene International Share<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Parameter<\/th>\n<th>Details<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Company<\/td>\n<td><a href=\"https:\/\/univest.in\/stocks\/syngene\/syngene-international-ltd-share-price-today\">Syngene International<\/a><\/td>\n<\/tr>\n<tr>\n<td>NSE Symbol<\/td>\n<td>SYNGENE<\/td>\n<\/tr>\n<tr>\n<td>Sector<\/td>\n<td>Contract Research<\/td>\n<\/tr>\n<tr>\n<td>CMP (Approx)<\/td>\n<td>Rs 400<\/td>\n<\/tr>\n<tr>\n<td>52-Week High<\/td>\n<td>Rs 520<\/td>\n<\/tr>\n<tr>\n<td>52-Week Low<\/td>\n<td>Rs 350<\/td>\n<\/tr>\n<tr>\n<td>Market Cap<\/td>\n<td>Rs 16,413 Cr<\/td>\n<\/tr>\n<tr>\n<td>P\/E Ratio<\/td>\n<td>74.33<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><em>Note: Data approx. as of 6 Aug 2026. Verify on nseindia.com.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Pros_of_Investing_in_Syngene_International_Share\"><\/span><strong>Pros of Investing in Syngene International Share<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"1_Integrated_CDMO_Covering_Drug_Discovery_to_Commercial_Manufacturing_%E2%80%94_Rare_Capability\"><\/span><strong>1. Integrated CDMO Covering Drug Discovery to Commercial Manufacturing \u2014 Rare Capability<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Syngene provides the full drug development value chain \u2014 early-stage chemistry research through pre-clinical biology, toxicology, clinical batch manufacturing, and commercial API production \u2014 enabling global pharma companies to have a single CDMO partner rather than multiple vendors for different development stages. This integrated capability is rare and creates sticky client relationships.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"2_Global_Pharma_Client_Base_%E2%80%94_Bristol-Myers_Squibb_Abbott_Amgen_%E2%80%94_Validating_Quality\"><\/span><strong>2. Global Pharma Client Base \u2014 Bristol-Myers Squibb, Abbott, Amgen \u2014 Validating Quality<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Syngene&#8217;s client roster includes Bristol-Myers Squibb (dedicated research facility on Syngene campus), Abbott, and 400-plus global pharma and biotech companies, validating its research infrastructure, regulatory compliance, and data integrity standards to the highest global pharmaceutical quality requirements.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"3_Biocon_Group_Promoter_Providing_Pharmaceutical_Industry_Knowledge_and_Client_Relationships\"><\/span><strong>3. Biocon Group Promoter Providing Pharmaceutical Industry Knowledge and Client Relationships<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Syngene benefits from Biocon Group&#8217;s deep pharmaceutical industry knowledge, regulatory expertise, and client relationships across global biotech and specialty pharma companies. This promoter ecosystem provides Syngene with deal flow and credibility that independent CDMOs must build from scratch.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"4_Global_CDMO_Industry_Tailwind_%E2%80%94_Drug_Discovery_Outsourcing_Growing_12_to_15_Percent\"><\/span><strong>4. Global CDMO Industry Tailwind \u2014 Drug Discovery Outsourcing Growing 12 to 15 Percent<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The global CDMO market is growing at 12 to 15 percent annually as pharmaceutical companies increase research outsourcing to reduce fixed costs, access specialist capabilities, and accelerate drug development timelines. India&#8217;s lower cost base and strong chemistry education system make Syngene structurally competitive in this growing market.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"5_Dedicated_Research_Facility_Infrastructure_on_Mangalore_Campus_Attracting_Long-Term_Partners\"><\/span><strong>5. Dedicated Research Facility Infrastructure on Mangalore Campus Attracting Long-Term Partners<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Syngene&#8217;s dedicated research facilities \u2014 where global pharma companies establish long-term research partnerships with dedicated Syngene scientists working exclusively on their programmes \u2014 create 10-plus year revenue visibility from committed research relationships that conventional fee-for-service CDMOs do not generate.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Cons_of_Investing_in_Syngene_International_Share\"><\/span><strong>Cons of Investing in Syngene International Share<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"1_PE_of_74x_Is_Expensive_for_CDMO_in_Investment_Phase_With_Low_ROE_of_78_Percent\"><\/span><strong>1. PE of 74x Is Expensive for CDMO in Investment Phase With Low ROE of 7.8 Percent<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>At 74x PE with ROE of only 7.76 percent, the Syngene share appears very expensive for current earnings delivery. The low ROE reflects the heavy capital investment in new CDMO infrastructure for biological manufacturing and commercial API scale-up that temporarily suppresses returns.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"2_ROE_of_776_Percent_Is_Well_Below_Quality_Threshold_%E2%80%94_Investment_Cycle_Impact\"><\/span><strong>2. ROE of 7.76 Percent Is Well Below Quality Threshold \u2014 Investment Cycle Impact<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Syngene&#8217;s current ROE of approximately 7.76 percent is significantly below the 15 percent quality benchmark, reflecting capital expenditure in new manufacturing facilities, equipment, and quality systems that precede revenue generation. Until these investments reach productive capacity, ROE improvement is gradual.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"3_Global_Pharma_CDMO_Competition_From_WuXi_AppTec_and_Samsung_Biologics\"><\/span><strong>3. Global Pharma CDMO Competition From WuXi AppTec and Samsung Biologics<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Syngene competes with WuXi AppTec (China&#8217;s largest CDMO), Samsung Biologics (Korea&#8217;s pharmaceutical biologics CDMO), and Lonza (Switzerland&#8217;s chemical CDMO) for large global pharmaceutical outsourcing contracts. These competitors have significantly larger scale and sometimes lower cost structures than Syngene for specific CDMO service categories.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"4_Client_Programme_Cancellation_Risk_%E2%80%94_Early-Stage_Drug_Failures_Reduce_Research_Revenue\"><\/span><strong>4. Client Programme Cancellation Risk \u2014 Early-Stage Drug Failures Reduce Research Revenue<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>A significant portion of Syngene&#8217;s research revenue comes from early-stage drug discovery programmes for global pharma clients. When a client drug candidate fails in pre-clinical or Phase I clinical trials, Syngene&#8217;s associated research programme is cancelled \u2014 creating revenue volatility from the inherent failure rate of pharmaceutical R&amp;D.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Use the Univest Screener to Analyse Stocks for Free<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Is_Syngene_International_Share_a_Good_Investment_in_2026\"><\/span><strong>Is Syngene International Share a Good Investment in 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Syngene International share is India&#8217;s finest CDMO investment with genuine integrated capabilities and global pharma validation. The 74x PE is expensive for current ROE during the investment phase. Consider as a premium healthcare technology allocation for investors with 5-plus year CDMO industry conviction.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_of_Syngene_International_Share\"><\/span><strong>Key Risks of Syngene International Share<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li>Major dedicated research partner (BMS) reducing Syngene research programme scope<\/li>\n<li>Global pharma company pipeline failures reducing early-stage research outsourcing demand<\/li>\n<li>WuXi AppTec or Lonza winning key Syngene commercial manufacturing contracts<\/li>\n<li>Capital investment programme cost overruns further suppressing ROE below current levels<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Syngene International share offers integrated cdmo covering drug discovery to commercial manufacturing \u2014 rare capability as a primary investment case. Weigh risks around pe of 74x is expensive for cdmo in investment phase with low roe of 7.8 percent carefully. Use Univest Screener for peer comparison and consult a SEBI-registered advisor.<\/p>\n<p style=\"margin-top: 24px;\"><em>Download the <a href=\"https:\/\/apps.apple.com\/in\/app\/univest-stock-market-research\/id1576403520\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"https:\/\/play.google.com\/store\/apps\/details?id=com.univest.stockmarket\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Syngene International share price live.<\/em><\/p>\n<div style=\"background: #CC0000; border-radius: 8px; padding: 16px 20px; margin: 24px 0;\">\n<p style=\"color: #ffffff; font-size: 13px; line-height: 1.7; margin: 0;\"><strong style=\"color: #ffffff;\">Disclaimer:<\/strong> Data from publicly available sources. May not be accurate. Verify on nseindia.com and bseindia.com. Not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions_on_Syngene_International_Share\"><\/span><strong>Frequently Asked Questions on Syngene International Share<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_main_pros_of_Syngene_International_share\"><\/span><strong>What are the main pros of Syngene International share?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Syngene International share offers integrated CDMO covering drug discovery to commercial manufacturing as a rare global capability, global pharma client base including BMS and Amgen validating quality standards, Biocon Group pharmaceutical industry knowledge and client relationships, global CDMO market growing at 12 to 15 percent from outsourcing expansion, and dedicated facility partnerships creating 10-plus year revenue visibility.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_key_risks_of_Syngene_International_share\"><\/span><strong>What are the key risks of Syngene International share?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Syngene International share faces PE of 74x expensive for CDMO in investment phase, ROE of 7.76 percent below quality threshold from capital expenditure, global CDMO competition from WuXi AppTec and Lonza with larger scale, and client programme cancellation risk from pharmaceutical R&amp;D failure rates. Monitor quarterly revenue growth and capital expenditure-to-revenue ratio.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Syngene_International_share_a_good_investment_in_2026\"><\/span><strong>Is Syngene International share a good investment in 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Syngene International share is India&#8217;s finest CDMO at expensive 74x PE with ROE in investment phase. Consider for premium healthcare technology allocation with 5-plus year conviction. Consult a SEBI-registered advisor. This is not investment advice.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_52-week_range_of_Syngene_International_share\"><\/span><strong>What is the 52-week range of Syngene International share?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Syngene International share has a 52-week high of approximately Rs 520 and a 52-week low of approximately Rs 350. Verify current data on NSE India at nseindia.com.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_a_CDMO_and_how_does_Syngene_provide_this_service\"><\/span><strong>What is a CDMO and how does Syngene provide this service?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> A CDMO (Contract Development and Manufacturing Organisation) provides outsourced drug development and manufacturing services to pharmaceutical and biotech companies that want to focus on drug discovery and marketing rather than owning research infrastructure and manufacturing plants. Syngene takes a global pharma company&#8217;s early drug candidate and provides chemistry research, biology testing, toxicology studies, formulation development, and eventually manufactures the drug substance at commercial scale under Good Manufacturing Practice (GMP) standards.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_BMS_dedicated_research_facility_at_Syngene\"><\/span><strong>What is the BMS dedicated research facility at Syngene?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Bristol-Myers Squibb (BMS) has established a dedicated research facility on Syngene&#8217;s Bengaluru campus where a dedicated Syngene research team works exclusively on BMS drug discovery programmes under long-term research collaboration agreements. This dedicated model \u2014 where a global pharma company commits to multi-year research spending with a dedicated Syngene team \u2014 provides highly predictable revenue and deep research integration that fee-for-service research cannot replicate. The BMS relationship is Syngene&#8217;s flagship partnership demonstrating the quality of its integrated CDMO model.<\/p>\n<div class=\"faq-schema\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Syngene International share pros and cons: Biocon&#8217;s CDMO subsidiary at 74x PE in investment phase analysed for 2026.<\/p>\n","protected":false},"author":34,"featured_media":190785,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3802],"class_list":["post-190786","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["190785"],"_edit_lock":["1786088309:37"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["63"],"rank_math_title":["Syngene International Share Pros and Cons 2026: Biocon's Contract Research Subsidiary"],"rank_math_description":["Syngene International share pros and cons: full-service contract research and manufacturing organisation, Biocon Group backing, and CDMO global demand vs high PE of 74x and ROE of 7.8 percent in investment phase."],"rank_math_focus_keyword":["Syngene International Share Pros and Cons"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"],"_edit_last":["37"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["34987"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/08\/pros-cons-investing-syngene-share.png","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/190786","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/34"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=190786"}],"version-history":[{"count":2,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/190786\/revisions"}],"predecessor-version":[{"id":190819,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/190786\/revisions\/190819"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/190785"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=190786"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=190786"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=190786"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}